A Phase Ib Study of AZD1775 and Olaparib in Patients with Refractory Solid Tumors
The purpose of this study is to find the highest doses of AZD1775 and olaparib that can be given together in patients with advanced solid tumors that continue to grow despite other treatments. Both of these drugs are designed to block DNA repair in cancer cells.
AZD1775 is an investigational drug that could prevent a protein called Wee1 from stopping the cancer cell to repair DNA damage. Olaparib blocks the DNA repair effects of the PARP protein, thereby causing cancer cells to die. Olaparib is approved for treating women with recurrent ovarian cancer; its use in combination with AZD1775 in this study is considered investigational. Both AZD1775 and olaparib are taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an advanced solid tumor that is not considered curable.
- Patients must have received at least one prior course of systemic cancer therapy.
- Patients must recover from the serious side effects of previous treatments before entering the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Bob Li at 646-888-4226.